Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Press releases

Stay current with the latest press releases from within the industry.

Active Biotech Advances 57-57 Project

Release issued 19th December 2005

Lund, Sweden - 19 December 2005 - Active Biotech (Stockholm: ACTI.ST) has commenced screening of patients in a Phase I clinical trial of the 57-57 Project for Systemic Lupus Erythematosus (SLE). Also patients with Reumatoid Arthritis (RA) will be included in the study. The clinical trial, the second of a planned series of Phase I studies, will primarily examine the safety and pharmacokinetics of 57-57.

In addition, a number of biological markers will be monitored to determine the effect of 57-57 on disease progression.

This multi-centre dose-escalation study is being conducted at three hospitals in Sweden - the Karolinska University Hospital in Stockholm, the Uppsala University Hospital in Uppsala, and the Lund University Hospital in Lund. Dr. Anders Bengtsson of the Lund University Hospital is the principal investigator for the trial.

SLE is a chronic rheumatic disease that affects joints, muscles and other parts of the body. An estimated 500,000 Americans have been diagnosed with SLE; however, surveys indicate that the prevalence may be much higher.

Phase II/III clinical trials of 57-57 are planned for 2007.

As previously reported, Active Biotech completed the first Phase I study of 57-57 earlier this year. That study, which examined the safety and pharmacokinetics of the drug in 30 healthy volunteers, was conducted at the Karolinska University Hospital in Stockholm. Results from the study showed that 57-57 was very well tolerated in all of the studied dose levels, both as single and repeated doses, and it is well suitable to be administered orally as a daily treatment.

Lund 19 December, 2005 Active Biotech AB (publ) Sven Andréasson President & CEO

For further information, please contact:

Sven Andréasson, President & CEO, phone: +46 46-19 20 49 Tomas Leanderson, CSO, phone: +46 46-19 20 95 Cecilia Hofvander, Manager Corporate Communication, phone: +46 46-19 11 22

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA.

Active Biotech AB Box 724, SE-220 07 Lund Tel: +46 46-19 20 00 Fax: +46 46-19 20 50 www.activebiotech.com

Company details

If you want to find out more about the company visit Active Biotech profile.

Latest Active Biotech press releases

Partnering consultation free of charge
Need competitive intelligence information
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us